Startup
Orizuru Therapeutics
オリヅルセラピューティクス株式会社
#47 in the Japan Top 100 Startups
| Founded / HQ | 2021 · Fujisawa, Kanagawa |
|---|---|
| Equity raised to date | ≥ ¥9.5B “第三者割当増資で95億円超” Company-stated cumulative · as of 29 Feb 2024 · Orizuru Therapeutics |
| Last round | 7 Aug 2026 · Additional investment · ¥300M 約3億円（追加出資） |
| Latest public valuation | Not publicly disclosed (we do not estimate) |
| Key investors | Kyoto University Innovation Capital, MUFG Bank, SMBC Venture Capital |
| Unicorn | No |
| Website | orizuru-therapeutics.com |
From Japanese sources
Findings from Japanese-language filings, government records, trade press, interviews and job posts, with our English analysis. Items tagged Japanese-only had no English coverage when we checked quickly. Most insightful first.
| 2026-07-28 | Regulatory filingJapanese-onlyOrizuru Therapeutics FY3/2026: ¥2.27B loss; total assets down 66% to ¥1.07B; deficit ¥9.74B オリヅルセラピューティクス株式会社 第5期決算公告 Total assets of the Kyoto iPS-cell spin-out (spun out of Takeda's T-CiRA) fell by two-thirds in a year to about ¥1.07B, against a ¥2.27B annual loss. That is under a year of runway at the current burn, so a raise, partnering deal or cuts look imminent. The pressure resembles Megakaryon's, suggesting Kyoto's iPS startups face a funding squeeze. Source: 官報決算データベース (statutory notice) |
|---|
Overview
Orizuru Therapeutics develops iPS-cell-based therapies and drug-discovery technologies. It was founded in 2021 and is led by CEO Takeshi Nonaka. Its February 2024 Series B of about ¥3.3B took equity funding above ¥9.5B.
Built from: Series B release
Company timeline
Founded
| Date | 2021-04-09· Orizuru Therapeutics |
|---|---|
| Founders | Takeshi Nonaka |
Funding
| Date | Round | Amount | Lead / key investors | Source |
|---|---|---|---|---|
| 2024-02-29 | Series B | ≈¥3.3B; equity cumulative >¥9.5B 第三者割当増資で95億円超 | Company release |
Key hires & board
None compiled yet.
Milestones
| 2026-03-16 | ProductPoster at 25th Japanese Society for Regenerative Medicine meeting· Orizuru |
|---|
News
| 2026-07-08 | Researcher interview published 研究員のインタビュー記事が掲載されました· Orizuru |
|---|---|
| 2026-05-08 | Lecture at Shonan iPark Festa 2026 湘南アイパークフェスタ2026にて講演会を開催します· Orizuru |
| 2026-03-16 | Poster at 25th Japanese Society for Regenerative Medicine meeting 第25回日本再生医療学会総会にてポスター発表を行います· Orizuru |
| 2026-02-24 | Speaking at AMED regenerative medicine symposium 令和7年度AMED再生・細胞医療・遺伝子治療公開シンポジウムに登壇します· Orizuru |
| 2026-02-03 | Special lecture at Japan Pancreas and Islet Transplantation meeting 第53回 日本膵・膵島移植学会学術集会にて特別講演を開催します· Orizuru |
| 2025-12-02 | Speaking at 10th DIA regenerative medicine symposium 第10回DIA再生医療製品・遺伝子治療用製品シンポジウムに登壇します· Orizuru |
| 2025-10-02 | Speaking at BioJapan 2025 BioJapan 2025に登壇します· Orizuru |
| 2025-10-02 | Speaking at Nakanoshima Qross forum in Yokohama Nakanoshima Qross Future Medicine Forum in YOKOHAMAに登壇します· Orizuru |
| 2025-10-02 | Spoke at 5th Annual iPSC Drug Development Summit The 5th Annual iPSC Drug Development Summitに登壇しました· Orizuru |
| 2025-08-20 | Public lecture on regenerative medicine 再生医療についての市民公開講座を開催します· Orizuru |
| 2024-02-29 | Series B: ≈¥3.3B; equity cumulative >¥9.5B· Company release |
Founder profiles: Kenji Nonaka
Funding rounds in 2026
Amounts are the full announced figure. Grey amounts aren't counted in equity totals. † includes debt, grants or other non-equity (hover for detail).
| Date | Company | Stage | Amount | Investors | Sector |
|---|---|---|---|---|---|
| 7 Aug 2026 | | Additional investment | ¥300M | Kyoto University Innovation Capital | BiotechDeep tech |